New Pharmacological Approaches to Therapy of NIDDM
- Rubin Bressler, MD and
- David Johnson, MD
- Departments of Internal Medicine and Pharmacology, The University of Arizona Health Sciences Center Tucson, Arizona
- Address Correspondence and Reprint Requests to Rubin Bressler, MD, Professor of Medicine and Head Dept. of Internal Medicine, The University of Arizona Health Sciences Center, 1501 North Campbell Avenue, Tucson, AZ 85724.
Abstract
Currently available pharmacological agents have not been completely successful in restoring euglycemia in the non-insulin-dependent diabetes mellitus (NIDDM) patient. Several new approaches to the therapy of NIDDM have been formulated in recent years and are in various stages of laboratory or pharmaceutical development. Several of these agents are discussed in this article under categories relating to their mechanisms of lowering blood glucose: 1) inhibition of the release or action of counterregulatory hormones; 2) inhibition of postprandial glucose rise; 3) sensitization of tissues to insulin's actions; and 4) inhibition of gluconeogenesis, including inhibition of the long-chain acyl-CoA-carnitine acyltransferase I, the long-chain acylcarnitine translocase, and pyruvate carboxylase.
- Copyright © 1992 by the American Diabetes Association
